Nasdaq:US$18.12 (-0.52) | HKEX:HK$28.75 (-0.90) | AIM:£2.93 (-0.03)
上一篇文章   |   下一篇文章
公告及新聞稿, 集團 | 2020-06-26

和黃醫藥計劃公佈2020年中期業績 (只備英文版本)

London: Friday, June 26, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on Thursday, July 30, 2020 at 12:00 noon British Summer Time (BST) (7:00 pm Hong Kong Time (HKT); 7:00 am Eastern Daylight Time (EDT)).
Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by Chi-Med management.
The conference call and audio webcast will take place at 1:00 pm BST / 8:00 pm HKT / 8:00 am EDT on Thursday, July 30, 2020 and will be webcast live via the company website at  The presentation will be available for downloading before the conference call begins. Details of the conference call dial-in will be provided in the financial results announcement and on the company website.  A replay will also be available on the website shortly after the event.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.  It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit:



Investor Enquiries

Mark Lee, Senior Vice President
+852 2121 8200

Annie Cheng, Vice President
+1 (973) 567 3786


Media Enquiries

Americas – Brad Miles, Solebury Trout
+1 (917) 570 7340 (Mobile)

UK & Europe –Ben Atwell / Alex Shaw, FTI Consulting
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

Asia – Joseph Chi Lo, Brunswick
+852 9850 5033 (Mobile)

Zhou Yi, Brunswick
+852 9783 6894 (Mobile)


Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited
+44 (20) 7886 2500